Business
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45pm PST.
About this update from Jp Morgan Chase & Co.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45pm PST.","length":396,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":263,"url":"https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7kIIgx9lBKLOOeuEoOJXpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d","width":400,"height":263}},"href":"https://mma.prnewswire.com/media/820568/IDEAYA_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""2025 was a year of execution, marked by broad pipeline advancement, commercial readiness activities for darovasertib, and the filing of four INDs resulting in nine clinical programs. Our deep pipeline and cash runway into 2030 enable IDEAYA to advance key combinations and to address multiple indications with high unmet need, including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted lung, pancreatic, and urothelial cancers. In 2026, we plan to advance four registrational trials, including for IDE849, our Phase 1 DLL3 TOP1 ADC, as a monotherapy agent in neuroendocrine cancer, and darovasertib in both pre-metastatic and metastatic settings of uveal melanoma. These trials for darovasertib are central to our strategy to save eyes, preserve vision, and extend lives for patients with uveal melanoma - one of the poorest prognosis indications in oncology where the majority of patients have no available FDA approved therapies," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.","length":1071,"tagName":"p"},{"type":"text","content":"2026 Corporate Objectives","length":25,"tagName":"p"},{"type":"text","content":"Darovasertib in uveal melanoma (UM)","length":35,"tagName":"...